Effect of oversulfated dermatan sulfate derivatives on platelet aggregation

Thrombosis Research

Volumn 120, Issue 4, 2007, Pages 615-621

  Maaroufi, Raoui M ^a   Giordano, Paola ^b   Triadou, Patrick ^c   Tapon Bretaudière, Jacqueline ^d   Dautzenberg, Marie Dominique ^c   Fischer, Anne Marie ^d  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b Dipartimento Biomedicina Del Eta Evolutiva   (Italy)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Aggregation; Antithrombin; Coagulation; Dermatan sulfate; Heparin cofactor II; Platelets

Indexed keywords

ANTITHROMBIN; ARACHIDONIC ACID; COLLAGEN; DERMATAN SULFATE DERIVATIVE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN COFACTOR II; THROMBIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG INHIBITION; DRUG POTENCY; ENZYME INHIBITION; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SULFATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADULT; ANTICOAGULANTS; ANTITHROMBIN III; ARACHIDONIC ACID; COLLAGEN; DERMATAN SULFATE; HEPARIN; HEPARIN COFACTOR II; HUMANS; PLATELET AGGREGATION; THROMBIN;

EID: 34447634701     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.10.023     Document Type: Article

References (39)

1. Ofosu F.A., Modi G.J., Blajchman M.A., Buchanan M.R., and Johnson E.A. Increased sulfation improves the anticoagulant activities of heparan sulfate and dermatan sulfate. Biochem J 248 (1987) 889-896
2. Maaroufi R.M., Tapon-Bretaudière J., Mardiguian J., Sternberg C., Dautzenberg M.D., and Fischer A.-M. Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives. Thromb Res 59 (1990) 749-758
3. Maaroufi R.M., Jozefonwicz M., Tapon-Bretaudière J., Jozefowicz J.M.D., and Fischer A.-M. Mechanism of inhibition of thrombin heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative. Biomaterials 18 (1997) 359-366
4. Maaroufi R.M., Jozefonwicz M., Tapon-Bretaudière J., and Fischer A.-M. Thrombin inhibition by antithrombin in the presence of oversulfated dermatan sulfates. Cabohydr Res 341 5 (2006) 672-676
5. Da Silva M.S., and Sobel M. Anticoagulants: to bleed or not to bleed, that is the question. Semin Vasc Surg 15 4 (2002) 256-267
6. Messmore H.L., Griffin B., Koza M., Seghatchian J., Fareed J., and Coyne E. Interaction of heparinoids with platelets: comparison of heparin and low molecular weight heparins. Semin Thromb Haemost 17 1 (1991) 57-59
7. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121 4 (2003) 535-555
8. Mousa S.A. Heparin and low molecular weight heparin in thrombosis and beyond. Curr Opin Investig Drugs 3 8 (2002) 16824-16827
9. Desai U.R. New antithrombin-based anticoagulants. Med Res Rev 24 2 (2004) 151-181
10. Hoppensteadt D., Walenga J.M., Fareed J., and Bick R.L. Heparin, low molecular weight heparins and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am 17 1 (2003) 313-341
11. Sinniger V., Tapon-Bretaudière J., Zhou F.L., Bros A., Muller D., Jozefonvicz J., et al. Immobilization of dermatan sulphate on a silica matrix and its possible use as an affinity chromatography support for heparin cofactor II purification. J Chromatogr 539 2 (1991) 289-296
12. Josso F., Rio I., and Beguin S. A new variant of human prothrombin: prothrombin Metz, demonstration in a family showing double heterozygosity for congenital hypoprothrombinemia and dysprothrombinemia. Haemostasis 12 (1982) 309-316
13. Triadou P., Fonty E., Ambrosio A.S., Cottat M.C., and Girot R. Platelet function in sickle cell disease during steady state. Nouv Rev Fr Hematol 32 (1990) 137-142
14. Sié P., Fernandez F., Caranobe C., Gabaig A.M., and Boneu B. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate. Thromb Res 35 (1984) 231-236
15. Luzzatto G., Paolini R., Stevanato F., Simioni P., and Cella G. Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin. Angiology 40 3 (1989) 170-174
16. Cella G., Scattolo N., Luzzatto G., Stevanato F., Vio C., and Girolami A. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf. J Med 17 5-6 (1986) 331-346
17. Mascellani G., Liverani L., Bianchini P., Parma B., Torri G., Bisio A., et al. Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate. Biochem J 293 (1993) 639-648
18. Bossennec V., Petitou M., and Perly B. 1H-NMR investigation of naturally occurring and chemically oversulphated dermatan sulphates. Identification of minor monosulphate residues. Biochem J 267 (1990) 625-630
19. Choay J., Petitou M., Lormeau J.C., Sinay P., Casu B., and Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116 (1983) 492-499
20. Agnelli G., Iorio A., de Angelis V., and Nenci G.G. Dermatan sulfate in heparin-induced thrombocytopenia. Lancet 344 (1994) 1295-1296
21. Chong B.H. Heparin-induced thrombocytopenia. J Thromb Haemost 1 7 (2003) 1471-1478
22. Vicente C.P., He L., Pavao M.S., and Tollefsen D.M. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood 104 13 (2004) 3965-3970
23. Liaw P.C., Becker D.L., Stafford A.L., Fredenburgh J.C., and Weitz J.L. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276 24 (2001) 20959-20965
24. Cofrancesco E., Colombi M., Gianese F., and Cortellaro M. The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and beta TG/PF4 release. Thromb Res 57 3 (1990) 405-414
25. Hoppensteadt D.A., Walenga J.M., and Fareed J. Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin. Semin Thromb Hemost 17 Suppl. 1 (1991) 60-64
26. Amiral J., Wolf M., Fischer A.-M., Boyer-Neuman C., Vissac A.-M., and Meyer D. Pathogenicity of IgA and/or IgM antibodies in patients with heparin-induced thrombocytopenia. Br J Haematol 92 (1996) 954-959
27. Jeske W.P., and Walenga J.M. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Curr Opin Investig Drugs 3 8 (2002) 1171-1180
28. Lindhoff-Last E., Kreutzenbeck H.J., and Magnani H.N. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 93 1 (2005) 63-69
29. Chong B.H., Ismail F., Cade J., Gallus A.S., Gordon S., and Chesterman C.N. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoïd, Org 10172. Blood 73 (1989) 1592-1596
30. Magnani H.N. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 70 (1993) 554-561
31. Burgess J.K., and Chong B.H. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 58 4 (1997) 279-285
32. Barbanti M., Calanni F., Milani M.R., Marchi I., Semeraro N., and Colucci M. Therapeutic effect of a low molecular weight dermatan sulfate (Desmin 370) in rat venous thrombosis - evidence for anticoagulant-independent mechanism. Thromb Haemost 69 2 (1993) 147-151
33. Barbanti M., Calanni F., Marchi E., Semeraro N., and Colucci M. Desmin 370, a low molecular weight dermatan sulfate, reduced the weight of performed thrombi in rats made afibrinogenemic by ancrod. Thromb Haemost 73 2 (1995) 287-290
34. Dettori A.G., Galli M., Manotti C., and Palazzini E. Pharmacological activity of a low molecular weight dermatan sulfate (Desmin), in healthy volunteers. Semin Thromb Haemost 20 3 (1994) 259-265
35. Hennan J.K., Hong T.T., Shergill A.K., Driscoll E.M., Cardin A.D., and Lucchesi B.R. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther 301 3 (2002) 1151-1156
36. Hong T.T., Van Gorp C.L., Cardin A.D., and Lucchesi B.R. Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury. Thromb Res 117 (2006) 333-342
37. Tanaka K.A., Szlam F., Vinten-Johansen J., Cardin A.D., and Levy J.H. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. Thromb Haemost 94 4 (2005) 808-813
38. Casu B., Naggi A., and Torri G. Chemical derivatization as a strategy to study structure-activity relationships of glycosaminoglycans. Semin Thromb Hemost 28 4 (2002) 335-342
39. Vicente C.P., Zancan P., Peixoto L.L., Alves-Sa R., Araujo F.S., Mourao P.A., et al. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding. Thromb Haemost 86 5 (2001) 1215-1220